Mariner
LXRX icon

Mariner’s Lexicon Pharmaceuticals LXRX Stock Holding History

Mariner’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.3K Buy
+11,072
New +$16.1K ﹤0.01% 3498

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Mariner's LXRX Position: Q1 2026 in Review

Mariner opened a new position in Lexicon Pharmaceuticals (LXRX) in Q1 2026: 11,072 shares worth $17.3K. The stake represents ﹤0.01% of the portfolio and ranks #3498 among its holdings.

136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Mariner held 11,072 shares of Lexicon Pharmaceuticals worth $17.3K as of Q1 2026.
  • Lexicon Pharmaceuticals was a new Mariner position in Q1 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #3498 holding.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.